Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells

Immunology

Volumn 143, Issue 1, 2014, Pages 96-108

  Kerkar, Sid P ^a   Chinnasamy, Dhanalakshmi ^b   Hadi, Neima ^b   Melenhorst, Jan ^b   Muranski, Pawel ^b   Spyridonidis, Alexandros ^b   Ito, Sawa ^b   Weber, Gerrit ^c   Yin, Fang ^b   Hensel, Nancy ^b   Wang, Ena ^d   Marincola, Francesco M ^e   Barrett, Austin John ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Antigen presentation; Dendritic cells; Inflammation; Interferon ; T lymphocytes

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; EXPOSURE; GENE EXPRESSION PROFILING; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; UPREGULATION;

ANTIGEN PRESENTATION; DENDRITIC CELLS; INFLAMMATION; INTERFERON-Γ; T LYMPHOCYTES;

CELL DIFFERENTIATION; CELL LINE; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; MONOCYTES; TRANSCRIPTOME;

EID: 84904859831     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12292     Document Type: Article

References (57)

1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454:428-35.
2. Germain RN. Maintaining system homeostasis: the third law of Newtonian immunology. Nat Immunol 2012; 13:902-6.
3. Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol 2011; 11:221-30.
4. + T cells. Science 2010; 327:1098-102.
5. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487-501.
6. Young HA. Unraveling the pros and cons of interferon-γ gene regulation. Immunity 2006; 24:506-7.
7. Young HA, Bream JH. IFN-γ: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol 2007; 316:97-117.
8. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 1993; 11:571-611.
9. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Annu Rev Immunol 1997; 15:749-95.
10. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163-89.
11. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656-61.
12. Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965; 149:310-1.
13. Pan J, Zhang M, Wang J et al. Interferon-γ is an autocrine mediator for dendritic cell maturation. Immunol Lett 2004; 94:141-51.
14. Rojas D, Krishnan R. IFN-γ generates maturation-arrested dendritic cells that induce T cell hyporesponsiveness independent of Foxp3+ T-regulatory cell generation. Immunol Lett 2010; 132:31-7.
15. Zaidi MR, Merlino G. The two faces of interferon-γ in cancer. Clin Cancer Res 2011; 17:6118-24.
16. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon γ: implications for immune responses and autoimmune diseases. Immunity 2009; 31:539-50.
17. Matsuo M, Nagata Y, Sato E et al. IFN-γ enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc Natl Acad Sci U S A 2004; 101:14467-72.
18. + regulatory T cell promotion. J Immunol 2009; 183:2932-45.
19. Rojas-Canales D, Krishnan R, Jessup CF, Coates PT. Early exposure of interferon-γ inhibits signal transducer and activator of transcription-6 signalling and nuclear factor αβγκB activation in a short-term monocyte-derived dendritic cell culture promoting 'FAST' regulatory dendritic cells. Clin Exp Immunol 2012; 167:447-58.
20. Kerkar SP, Goldszmid RS, Muranski P et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011; 121:4746-57.
21. Gazzinelli RT, Wysocka M, Hayashi S et al. Parasite-induced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol 1994; 153:2533-43.
22. Bradley LM, Dalton DK, Croft M. A direct role for IFN-γ in regulation of Th1 cell development. J Immunol 1996; 157:1350-8.
23. Delneste Y, Charbonnier P, Herbault N et al. Interferon-γ switches monocyte differentiation from dendritic cells to macrophages. Blood 2003; 101:143-50.
24. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2:933-44.
25. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003; 21:713-58.
26. + T cells in anti-tumor immune responses. Immunol Rev 2008; 222:129-44.
27. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11:723-37.
28. Castiello L, Sabatino M, Jin P et al. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol Immunother 2011; 60:457-66.
29. Han TH, Jin P, Ren J, Slezak S, Marincola FM, Stroncek DF. Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-γ. J Immunother 2009; 32:399-407.
30. Vopenkova K, Mollova K, Buresova I, Michalek J. Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy. J Cell Mol Med 2012; 16:2827-37.
31. Goldszmid RS, Caspar P, Rivollier A et al. NK cell-derived interferon-γ orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 2012; 36:1047-59.
32. O'Garra A, Trinchieri G. Are dendritic cells afraid of commitment? Nat Immunol 2004; 5:1206-8.
33. Rojas-Canales D, Krishnan R, Jessup CF, Coates PT. Early exposure of interferon-γ inhibits signal transducer and activator of transcription-6 signalling and nuclear factor κB activation in a short-term monocyte-derived dendritic cell culture promoting 'FAST' regulatory dendritic cells. Clin Exp Immunol 2012; 167:447-58.
34. Lu J, Celis E. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Cancer Res 2000; 60:5223-7.
35. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330-42.
36. Thornton AM, Korty PE, Tran DQ et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010; 184:3433-41.
37. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26.
38. Steinman RM, Nussenzweig MC. Dendritic cells: features and functions. Immunol Rev 1980; 53:127-47.
39. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994; 179:1109-18.
40. + T-cell in humans without foreign helper epitopes. J Clin Invest 2000; 105:R9-14.
41. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193:233-8.
42. Esche C, Shurin MR, Lotze MT. The use of dendritic cells for cancer vaccination. Curr Opin Mol Ther 1999; 1:72-81.
43. Bluestone JA, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol 2007; 7:650-4.
44. Tran DQ, Shevach EM. Therapeutic potential of FOXP3(+) regulatory T cells and their interactions with dendritic cells. Hum Immunol 2009; 70:294-9.
45. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12:443-58.
46. Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12:1160-6.
47. Melenhorst JJ, Barrett AJ. Tumor vaccines and beyond. Cytotherapy 2011; 13:8-18.
48. Paulos CM, Suhoski MM, Plesa G et al. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res 2008; 42:182-96.
49. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81.
50. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3:35-45.
51. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol 2010; 22:251-7.
52. Bernatchez C, Radvanyi LG, Hwu P. Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol 2012; 39:215-26.
53. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9.
54. Demaria S, Pikarsky E, Karin M et al. Cancer and inflammation: promise for biologic therapy. J Immunother 2010; 33:335-51.
55. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-36.
56. + T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010; 70:6725-34.
57. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012; 72:3125-30.